Publication of the Individual financial statements for Q2 of 2025
Revenues for January-June 2025
Holding a Regular general meeting of shareholders of "Sopharma" AD
Revenues for January-May 2025
Notification from Alexander Tchaoushev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD as of 20 December 2024
Publication of the Consolidated financial statements for Q1 of 2025
Decision on additional contribution to the capital of Sopharma Rus OOO
Sofia, Bulgaria, December 20, 2024 – In accordance with the requirements of Art. 100t of the LPOS, Sopharma AD (SFA: Bulgarian Stock Exchange AD, SPH: Warsaw Stock Exchange) hereby informs that in order to ensure operational opportunities for growth and increase sales on the traditional markets where the Company operates, the Board of Directors has decided to make an additional contribution to its subsidiary “Sopharma Rus” OOO in the amount of EUR 12.3 million, not increasing the capital.
Revenues for January-April 2025
Transaction within the scope of art. 114, para. 2 of the Law on Public offering of securities
Sofia, Bulgaria, December 19, 2024 - Pursuant to the requirements of Article 100t of the LPOS and in conjunction with Article 114, par. 9 of the LPOS, "Sopharma" AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) hereby informs, that The Board of Directors, at its meeting held on December 19, 2024, in accordance with the requirements of art. 114, para 2 of the LPOS and in accordance with the Group's strategy for optimization and focus on health related activities, approved the conclusion of the following transaction: